问题 › 我们该进入新市场吗？ › 医疗服务提供商
合同吸引力是容易的一半。制胜权才是决定结果的那一半。 医疗服务提供商在此面临特定困境——已接受38,000人的下行风险，却缺乏定价所需的分次成本数据。在定价前，分次成本会因无人能归因的原因持续变动，而关于制胜权的讨论仍停留在意见层面。
合同吸引力是容易的一半。制胜权才是决定结果的那一半。 医疗服务提供商在此面临特定困境——已接受38,000人的下行风险，却缺乏定价所需的分次成本数据。在定价前，分次成本会因无人能归因的原因持续变动，而关于制胜权的讨论仍停留在意见层面。
新价值导向合同的评估依据是归属人数和增长，这两点都可知，但都无法预测成功。预测性问题是：你已有的哪些资源可以转移——一组服务提供商、现有合同的分次成本历史，或已建立的支付方组合——以及哪些必须从零开始构建。
一份合同可能吸引力很高，但对你而言是坏主意。反之亦然：归属人数不多、但你已掌控分次成本和每位提供商贡献的合同，通常优于从零开始的合同。
另一项纪律是进入前明确设定终止标准，因为价值导向合同特别容易在“快要成功”的理由下悄无声息地消耗预算多年。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 案例主要基于价值导向合同下的归属人数这一标题数字
✓ 无人写下触发退出的分次成本阈值
✓ 现有面板持平，新合同被要求解决每位提供商的贡献问题
通常会让情况更糟的做法。 因为当前归属人数停滞而进入，这会让CFO或医务主任的注意力从实际需要解决的分次成本问题上移开。
It is for you if you run or finance a healthcare provider and the case rests mainly on market size and growth rate. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Protect and grow the 34% operating-income ASC engine by replacing retiring surgeons and steering 212k attributed lives to the ASC within 24 months.
| Investment required | $3.0-4.0M total over 24 months ($1.8-2.2M surgeon succession + retention bonuses; $1.2-1.8M referral-optimization platform and analytics) |
| Expected return | Incremental $4.8-6.4M annual ASC contribution margin by Month 24; payback 14-18 months on $3.0-4.0M investment; lifts group operating margin from 4.2% to 5.8-6.4%. |
| Revenue, year 1 | $202-208M (ASC case volume +4-6%) |
| Revenue, year 2 | $212-220M (ASC case volume +6-8%; physician retention +2-3%) |
| Revenue, year 3 | $225-235M (ASC contribution ≥40% of operating income) |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than two qualified orthopaedic surgeon candidates have signed LOIs OR if ASC case volume has not grown at least 2% YoY; in either case, board must decide within 30 days whether to pivot to hospital-system sale process at 8-10× EBITDA. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 市场进入与扩张策略, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
列出新市场看重、而你已拥有的东西，以及可信在位者拥有而你没有的东西。如果第二份清单更长，且包含任何结构性要素——分销、监管、数据深度——进入就是一次构建，而非延伸。
在开始前设定数字，并将超过该数字视为终止标准，而非追加投资的理由。大多数失败的进入从未被终止，只是缓慢耗尽资源。
whichever reuses more of what you already have. Geography usually reuses the product and rebuilds distribution; a new segment usually reuses distribution and rebuilds the product. Whichever rebuild is smaller is the safer bet.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית